ArticleCarcinogenesis2015
The role of miR-200a in mammalian epithelial cell transformation.
Article in Carcinogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Impact of rs2107425 Polymorphism and Expression of lncH19 and miR-200a on the Susceptibility of Colorectal Cancer.Indian journal of clinical biochemistry : IJCB · 2023Article
- Review
- Combined analysis of miR-200 family and its significance for breast cancer.Scientific reports · 2021Article
- Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer/miR-16/JNK2/MMP-2 axis.Oncogene · 2020Article
- MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2.OncoTargets and therapy · 2019Article
- "Beige" Cross Talk Between the Immune System and Metabolism.Frontiers in endocrinology · 2019Article
- microRNA-200a-3p increases 5-fluorouracil resistance by regulating dual specificity phosphatase 6 expression.Experimental & molecular medicine · 2017Article
- Potential Contributions of miR-200a/-200b and Their Target Gene-Leptin to the Sexual Size Dimorphism in Yellow Catfish.Frontiers in physiology · 2017Article
- MicroRNA analysis of breast ductal fluid in breast cancer patients.International journal of oncology · 2016Article
- Thymosin beta 4 up-regulates miR-200a expression and induces differentiation and survival of rat brain progenitor cells.Journal of neurochemistry · 2016Article
- A feedback regulatory loop involving p53/miR-200 and growth hormone endocrine axis controls embryo size of zebrafish.Scientific reports · 2015Article
- Roles for miRNAs in endocrine resistance in breast cancer.Endocrine-related cancer · 2015Review
- Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- MicroRNA-200 promotes lung cancer cell growth through FOG2-independent AKT activation.IUBMB life · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Cancer is a multistep disease that begins with malignant cell transformation and frequently culminates in metastasis. MicroRNAs (miRNAs) are small regulatory 21-25 nt RNA molecules and are frequently deregulated in cancer. miR-200a is a member of the miR-200 family, which are known inhibitors of the epithelial-to-mesenchymal transition. As such, the tumor-suppressive role of miR-200a in oncogenesis has been well documented; however, recent studies have found a proliferative role for this miRNA as well as a prometastatic role in the later steps of cancer progression. Little is known about the role of this miRNA in the early stages of cancer, namely, malignant cell transformation. Here, we show that miR-200a alone transforms an immortalized rat epithelial cell line, and miR-200a cooperates with Ras to enhance malignant transformation of an immortalized human epithelial cell line. Furthermore, miR-200a induces cell transformation and tumorigenesis in immunocompromised mice by cooperating with a Ras mutant that activates only the RalGEF effector pathway, but not Ras mutants activating PI3K or Raf effector pathways. This transformative ability is in accordance with miR-200a targeting Fog2 and p53 to activate Akt and directly repress p53 protein levels, respectively. These results demonstrate an oncogenic role for miR-200a and provide a specific cellular context where miR-200a acts as an oncomiR rather than a tumor suppressor by cooperating with an oncogene in malignant cell transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.